A reduction in urinary albumin–creatinine ratio from baseline to month 4 was associated with a lower risk of the primary and kidney composite end points with a similar risk gradient for participants with and without type 2 diabetes (P-interaction: 0.10 and 0.19, respectively). Here, ALB is linked to type 2 diabetes mellitus.